SGLT2 Inhibitor Use in Chronic Kidney Disease
Indications and Benefits
- The American College of Cardiology and Kidney International recommend SGLT2 inhibitors for adults with chronic kidney disease without diabetes who have eGFR ≥20 mL/min/1.73 m² and urine albumin-to-creatinine ratio (ACR) ≥200 mg/g, or heart failure, regardless of albuminuria level, to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure 1, 2
- For patients with CKD without diabetes, SGLT2 inhibitors provide significant kidney protection and cardiovascular benefits, similar to those observed in patients with diabetes, with a strong recommendation for their use in very high-risk patients (eGFR <30 mL/min/1.73 m² with ACR ≥200 mg/g) 3, 4
Risk Stratification and Recommendations
- The British Medical Journal recommends a strong recommendation for SGLT2 inhibitor therapy in high-risk patients (eGFR 30-44 mL/min/1.73 m² with ACR ≥200 mg/g) and a weak recommendation for moderate-risk patients (eGFR 45-59 mL/min/1.73 m² with ACR 30-200 mg/g) 3
Specific Recommendations by GFR and Albuminuria
- The Kidney International guidelines strongly recommend the use of SGLT2 inhibitors in patients with eGFR ≥20 mL/min/1.73 m² and ACR ≥200 mg/g, or heart failure, regardless of albuminuria level 1, 2
Practical Considerations for Initiation and Monitoring
- Baseline assessment should include measurement of eGFR and urine ACR before starting SGLT2 inhibitor therapy, with monitoring of eGFR every 3-6 months if <60 mL/min/1.73 m², and annually if ≥60 mL/min/1.73 m² 5
- An initial, reversible decrease in eGFR (typically 3-5 mL/min/1.73 m²) is expected and not a reason to discontinue therapy, with SGLT2 inhibitors able to be continued even if eGFR falls below 20 mL/min/1.73 m², unless not tolerated or kidney replacement therapy is initiated 6, 2
Safety Considerations
- The Kidney International guidelines recommend temporarily withholding SGLT2 inhibitors during times of prolonged fasting, surgery, or critical medical illness when patients may be at greater risk for ketosis, and monitoring for genital mycotic infections and educating patients about symptoms of volume depletion 6, 2, 5
Combination Therapy
- SGLT2 inhibitors can be used alongside RAS inhibitors (ACEi or ARB) for enhanced kidney protection, with consideration of adding a nonsteroidal mineralocorticoid receptor antagonist (MRA) with proven kidney or cardiovascular benefit for patients with persistent albuminuria despite SGLT2 inhibitor and RASi therapy 1, 2
Evidence from Key Trials
- The DAPA-CKD trial demonstrated significant benefits of dapagliflozin in patients with CKD with and without diabetes, showing a 39% reduction in the primary composite endpoint of sustained decline in eGFR, end-stage kidney disease, or death 7
Limitations and Contraindications
- The Kidney International guidelines do not recommend SGLT2 inhibitors for patients with eGFR <20 mL/min/1.73 m² for initial therapy, or for patients with polycystic kidney disease or those requiring immunosuppressive therapy for kidney disease, and recommend against their use in kidney transplant recipients due to limited data and potential increased risk of infections 1, 2, 6